ALZpath and Siemens Healthineers have signed a licensing agreement to accelerate global access to blood-based Alzheimer’s disease diagnostic testing.
🔗Read the full press release: https://t.co/42MIvOfrKx
🧠 June is Alzheimer's & Brain Awareness Month.
This month, we recognize the individuals, families, caregivers and communities impacted by Alzheimer's disease, along with those dedicated to advancing awareness, research, diagnosis, and care.
#AlzheimersDisease#ENDALZ
🚨What if Alzheimer’s could be detected years - even decades - before symptoms begin? 🧠
That future is closer than most people realize. 🚀
On the latest episode of @ProgressPotent1 I sat down with Mike Banville, CEO of @AlZpath
After decades scaling global businesses, Mike is now focused on one of healthcare’s biggest challenges:
👉Making early, accessible Alzheimer’s detection a reality.
We explore:
• How ALZpath’s pTau217 antibody is enabling blood tests that may rival PET scans and spinal taps;
• Why earlier detection could reshape clinical trials, treatment timing, and patient outcomes;
• The bigger shift toward precision medicine and proactive brain health;
This isn’t just about diagnostics - it’s about changing when the fight against Alzheimer’s begins. ⚕️
#Alzheimers #BrainHealth #Biotech #EarlyDetection #PrecisionMedicine #HealthcareInnovation #Dementia #Neuroscience #Longevity @FINNPartners@FPIPR@SiemensHealth@Roche@RocheDiaUSA@BCILifeSciences@BeckmanDx
@Roche received CE Mark approval for the Elecsys pTau217 blood test, developed with @EliLillyandCo & powered by ADDF-funded @AlZpath’s pTau217 antibody. The approval marks another important step toward broader access to scalable Alzheimer’s diagnostics. https://t.co/ZhgwXfEFfz
With @adpdnet 2026 underway in Copenhagen, research featuring ALZpath’s pTau217 antibody appears across 29 scientific presentations.
Highlights from this week’s program below.
🔗 Read more: https://t.co/gNAMaMUxPS
1 week until AD/PD™ 2026 🧠
The global Alzheimer’s disease and Parkinson’s disease community will gather in Copenhagen, March 17–21.
Attending and want to connect? Reach out to Jacob Hunter at [email protected] to schedule a meeting.
We’re attending AD/PD 2026! ALZpath is excited to join the AD/PD™ 2026 Conference, March 17–21, in Copenhagen, Denmark.
If you will be attending and would like to connect, please reach out to Jacob Hunter at [email protected] to schedule a meeting.
#ADPD2026
🧠The words we use around brain health matter.
ALZpath has joined the Initiative to Change the “D-Word,” committing to remove outdated, stigmatizing language around cognitive impairment.
🔗Learn more in the full press release: https://t.co/tSLNmNACCa
We’re pleased to participate in the Global BioInnovation Forum today during @jpmorgan#JPM2026.
Our CEO Michael Banville will join a session moderated by @Gil_Bashe on how blood-based diagnostics are reshaping Alzheimer’s detection.
🕝 2:30 PM PT
🔗 https://t.co/298dESJJy2
Live at #CTAD25: the ALZpath #pTau217 antibody is accelerating biomarker, proteomic & longitudinal research across leading institutions.
🔗See the full list of posters & presentations: https://t.co/Tux252pqwt
📢#CTAD2025 is just two weeks away!
As we gear up to connect with leaders advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today🔗Explore: https://t.co/XYFTHe0CGm
Attending? Let’s connect: [email protected]
How reliable are blood-based pTau217 tests compared to PET or CSF?
Studies show blood tests powered by the #pTau217 antibody perform comparably to CSF tests for detecting Alzheimer’s disease - a major step toward earlier, more accessible diagnosis.
🔗 https://t.co/Ixgq0QDA3c
ALZpath’s proprietary #pTau217 antibody has been named Diagnostics Innovation of the Year by the 2025 #BioTechBreakthroughAwards — recognizing its impact in advancing earlier, more accessible #AlzheimersDisease detection.
🔗Read more: https://t.co/Ff8cu4yGgp
In a new article from @PMLiVEcom, ALZpath Distinguished Scientific Advisor Dr. Henrik Zetterberg shares three pillars advancing #Alzheimers blood testing - sensitivity, accessibility, and education - powered by #biomarkers like #pTau217.
🔗Read now https://t.co/HacAvjb1tM
We’re headed to #CTAD2025 in San Diego!
ALZpath will join global leaders in Alzheimer's disease research & diagnostics to discuss advances in #pTau217 and blood-based biomarkers.
Attending? Let’s connect - Reach out at [email protected] to schedule a meeting.
@CTADconference
@AlamarBio is advancing Alzheimer’s disease research with the launch of the NULISAqpcr™ BD-pTau217 Assay, built on ALZpath’s pTau217 antibody.
This launch broadens access to brain-specific blood-based biomarkers and marks another step forward in bringing innovative tools to AD.
🚀Just Launched: NULISAqpcr™ BD-pTau217 Assay! A game-changer in Alzheimer’s research—our new blood-based assay delivers unmatched sensitivity and CNS specificity for detecting brain-derived pTau217.
Learn more: https://t.co/5qpco6oGhb
Read the release: https://t.co/ztoXeJIlhx
The @US_FDA approved LEQEMBI® IQLIK™, a new at-home injectable that targets amyloid to help slow early #Alzheimers.
Weekly at-home care removes infusion visits and improves access. #EarlyDetection is key to ensuring patients can benefit most.
📖https://t.co/cv9WZoKk80